TRCT
CABA icon

Tower Research Capital (TRC)’s Cabaletta Bio CABA Stock Holding History

Tower Research Capital (TRC)’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.8K Buy
8,605
+2,821
+49% +$9.28K ﹤0.01% 3301
2026
Q1 		$15.6K Sell
5,784
-24,561
-81% -$68.2K ﹤0.01% 3662
2025
Q4 		$66.5K Buy
30,345
+25,978
+595% +$64.4K ﹤0.01% 2219
2025
Q3 		$10.2K Sell
4,367
-46,669
-91% -$80.1K ﹤0.01% 3992
2025
Q2 		$77.6K Buy
51,036
+44,621
+696% +$69.6K ﹤0.01% 2594
2025
Q1 		$8.88K Sell
6,415
-6,187
-49% -$13.2K ﹤0.01% 3845
2024
Q4 		$28.6K Buy
12,602
+1,504
+14% +$5.28K ﹤0.01% 2932
2024
Q3 		$52.4K Sell
11,098
-505
-4% -$2.92K ﹤0.01% 2697
2024
Q2 		$86.8K Buy
11,603
+11,150
+2,461% +$137K ﹤0.01% 2676
2024
Q1 		$7.73K Sell
453
-2,170
-83% -$46.6K ﹤0.01% 4153
2023
Q4 		$59.5K Buy
2,623
+1,042
+66% +$17.5K ﹤0.01% 3015
2023
Q3 		$24.1K Buy
1,581
+764
+94% +$10.4K ﹤0.01% 3204
2023
Q2 		$10.5K Sell
817
-4,205
-84% -$45.6K ﹤0.01% 4103
2023
Q1 		$42K Buy
5,022
+112
+2% +$1.05K ﹤0.01% 2653
2022
Q4 		$45K Sell
4,910
-12,628
-72% -$46K ﹤0.01% 2429
2022
Q3 		$11K Buy
17,538
+7,984
+84% +$9.61K ﹤0.01% 4426
2022
Q2 		$10K Sell
9,554
-8,886
-48% -$12.6K ﹤0.01% 4431
2022
Q1 		$37K Buy
18,440
+16,643
+926% +$43.5K ﹤0.01% 2956
2021
Q4 		$7K Buy
1,797
+355
+25% +$3.79K ﹤0.01% 4893
2021
Q3 		$18K Sell
1,442
-1,943
-57% -$17.9K ﹤0.01% 3808
2021
Q2 		$30K Buy
3,385
+1,802
+114% +$17.7K ﹤0.01% 3479
2021
Q1 		$18K Sell
1,583
-1,872
-54% -$22.9K ﹤0.01% 3956
2020
Q4 		$43K Sell
3,455
-9,178
-73% -$119K ﹤0.01% 3248
2020
Q3 		$137K Buy
12,633
+7,911
+168% +$90.9K ﹤0.01% 2897
2020
Q2 		$52K Buy
4,722
+1,755
+59% +$13.4K ﹤0.01% 3006
2020
Q1 		$22K Buy
2,967
+429
+17% +$5.88K ﹤0.01% 1661
2019
Q4 		$35K Buy
+2,538
New +$30.1K ﹤0.01% 1556

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Tower Research Capital (TRC)'s CABA Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Cabaletta Bio (CABA) stake by 49% in Q2 2026, buying an estimated $9.28K and bringing the position to 8,605 shares worth $26.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3301.

Tower Research Capital (TRC) first reported a position in CABA in Q4 2019 and has held it in 27 quarters since. The position peaked at $137K in Q3 2020. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Tower Research Capital (TRC) held 8,605 shares of Cabaletta Bio worth $26.8K as of Q2 2026.
  • Tower Research Capital (TRC) bought 2,821 Cabaletta Bio shares in Q2 2026, an estimated $9.28K.
  • Cabaletta Bio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3301 holding.
  • Tower Research Capital (TRC) first reported a position in Cabaletta Bio in Q4 2019 and has held it in 27 quarters since.
  • Tower Research Capital (TRC)'s Cabaletta Bio position peaked at $137K in Q3 2020.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.